New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 12, 2012
08:06 EDTVRTXVertex shares attractive, says ThinkEquity
After Vertex presented key efficacy and safety data for VX809 combination therapy, ThinkEquity believes that the data suggests that the therapy is providing a clinical benefit. The firm thinks that this benefit could be replicated in a Phase III study and it suggests owning the stock. ThinkEquity maintains a Buy rating on the shares.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:50 EDTVRTXVertex reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 29, 2014
09:09 EDTVRTXVertex was boosted by several catalysts, says RBC Capital
Subscribe for More Information
September 24, 2014
11:22 EDTVRTXOptions with increasing implied volatility
Subscribe for More Information
September 23, 2014
11:19 EDTVRTX Options with increasing implied volatility
Options with increasing implied volatility: HLF VRTX TRP CLX ETP VALE
07:55 EDTVRTXVertex should be bought into recent strength, says Wells Fargo
Subscribe for More Information
September 22, 2014
11:26 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: SHLD VRTX TRP AGNC
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
September 17, 2014
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use